中国P站

Myopia Control; Optical Interventions; Pharmacological Treatments; Atropine; Orthokeratology; Multifocal Contact Lenses; Spectacle Lenses; Axial Elongation; Pediatric Myopia; Visual Hygiene

Introduction

The increasing prevalence of myopia, particularly in children and adolescents, has become a significant public health concern worldwide, necessitating comprehensive strategies for its control and management [1].

Early intervention is paramount in mitigating the long-term consequences of myopia, including the risk of sight-threatening ocular pathologies later in life [1].

Various optical and pharmacological approaches have demonstrated efficacy in slowing the progression of refractive error and axial elongation [1].

Low-dose atropine has emerged as a prominent pharmacological intervention, with studies detailing its optimal concentration, administration protocols, and potential side effects [2].

Research suggests that this treatment significantly reduces axial elongation and refractive error progression in pediatric populations, with potential for enhanced outcomes when combined with other myopia control modalities [2].

Orthokeratology, commonly known as Ortho-K, represents a significant optical intervention that involves the overnight wear of specialized rigid gas permeable lenses [3].

This reshaping of the cornea effectively reduces refractive error and demonstrably slows axial elongation, highlighting the importance of precise lens fitting and consistent patient compliance for optimal results [3].

Multifocal contact lenses offer another crucial optical solution, designed with a dual-focus mechanism [4].

These lenses correct central vision while simultaneously inducing peripheral myopic defocus, a key factor believed to inhibit axial elongation and thus control myopia progression [4].

Clinical trial data supports their substantial efficacy in this regard [4].

Novel spectacle lens designs are also advancing the field of myopia control, with a focus on incorporating peripheral aberration control [5].

These lenses aim to create a dynamic peripheral defocus profile, thereby reducing stimuli that drive axial elongation [5].

This review encompasses both single-vision and multifocal spectacle lens designs within this innovative category [5].

The complex interplay between genetic predisposition and environmental influences plays a critical role in the progression of myopia [6].

Understanding these interactions is fundamental to developing effective 'myopia management' strategies, which aim to proactively mitigate the risks associated with high myopia and its associated complications [6].

Long-term studies are essential for evaluating the sustained effectiveness of myopia control interventions [7].

A significant cohort study providing a decade of data has demonstrated the lasting benefits of methods such as multifocal contact lenses and atropine in reducing the incidence of high myopia and its associated complications [7].

Delving deeper into the mechanisms of myopia control reveals the intricate roles of retinal defocus and ocular growth signaling pathways [8].

Both optical interventions and pharmacological agents are understood to influence these processes, ultimately contributing to the slowing of axial elongation [8].

Beyond clinical interventions, visual hygiene and lifestyle modifications are increasingly recognized for their role in myopia prevention and control [9].

Factors such as screen time, outdoor activity duration, and near work habits significantly impact myopia progression, and evidence-based recommendations for lifestyle changes are crucial complementary strategies [9].

Leading optometric organizations are continually refining clinical guidelines for myopia management, synthesizing current evidence to provide practical recommendations [10].

These updated approaches offer optometrists guidance on patient selection, treatment options, and monitoring protocols to ensure effective myopia control [10].

Description

The landscape of myopia control is rapidly evolving, driven by a growing understanding of its pathogenesis and the development of innovative therapeutic strategies [1].

A comprehensive overview of current myopia control methods, including their efficacy and underlying mechanisms, is vital for effective clinical practice [1].

These strategies range from optical interventions like specialized contact lenses and spectacle designs to pharmacological approaches such as low-dose atropine [1].

Pharmacological management of myopia has seen significant advancements, particularly with the use of low-dose atropine [2].

This treatment has been extensively studied for its optimal concentration, administration protocols, and safety profile [2].

Clinical evidence indicates that low-dose atropine effectively reduces axial elongation and slows refractive error progression in children, and its combination with other modalities may further enhance outcomes [2].

Orthokeratology (Ortho-K) stands out as a highly effective optical intervention for myopia control [3].

The nightly wear of Ortho-K lenses temporarily reshapes the cornea, correcting refractive error and significantly slowing axial elongation [3].

The success of Ortho-K treatment is contingent upon meticulous lens fitting and diligent patient adherence to the prescribed wear schedule [3].

Multifocal contact lenses represent another cornerstone of optical myopia control strategies [4].

Their unique design incorporates simultaneous central vision correction with the induction of peripheral myopic defocus [4].

This specific optical profile is theorized to inhibit axial elongation, and clinical studies have provided robust evidence of their efficacy in myopia control [4].

Advancements in spectacle lens technology are also contributing significantly to myopia management [5].

Novel spectacle lens designs focus on controlling peripheral aberrations and creating dynamic peripheral defocus profiles [5].

These innovations aim to reduce the visual stimuli that promote excessive axial elongation, with research encompassing both single-vision and multifocal lens designs [5].

Myopia progression is a complex phenomenon influenced by a confluence of genetic factors and environmental exposures [6].

Recognizing the intricate interplay between these elements is crucial for implementing effective 'myopia management' protocols [6].

Proactive management is essential to lower the risk of high myopia and its associated serious ocular complications [6].

Evaluating the long-term effectiveness of myopia control interventions is critical for informing clinical practice and patient outcomes [7].

A substantial longitudinal study tracking a large cohort of children over a decade has provided valuable data on the sustained efficacy of various interventions, including multifocal contact lenses and atropine, in preventing high myopia [7].

A deeper understanding of the physiological mechanisms driving myopia progression is essential for developing targeted interventions [8].

Research focuses on the role of retinal defocus, particularly peripheral defocus, and the complex signaling pathways that regulate ocular growth [8].

Both optical and pharmacological strategies are being investigated for their impact on these pathways [8].

Lifestyle and visual hygiene habits are increasingly recognized as important modifiable factors in myopia management [9].

Excessive near work, prolonged screen time, and insufficient outdoor exposure have been linked to increased myopia progression [9].

Evidence-based recommendations for lifestyle modifications can serve as a valuable adjunct to other myopia control strategies [9].

In parallel with research advancements, leading optometric organizations are issuing updated clinical guidelines for myopia management [10].

These guidelines synthesize the latest scientific evidence to provide practical, actionable recommendations for optometrists regarding patient assessment, treatment selection, and ongoing monitoring to ensure optimal myopia control [10].

Conclusion

This collection of articles reviews current myopia control strategies, encompassing optical and pharmacological interventions. It highlights the efficacy and mechanisms of multifocal contact lenses, orthokeratology, atropine eye drops, and novel spectacle lens designs in slowing myopia progression in children and adolescents. The importance of early intervention, genetic and environmental factors, visual hygiene, and lifestyle modifications are also discussed. Long-term studies provide evidence for the sustained effectiveness of these methods, and updated clinical guidelines offer practical recommendations for optometrists. The aim is to reduce the incidence of high myopia and associated ocular health complications.

References

1. Dr AS, Dr BC, Dr CD. (2023) .Optometry: Open Access 8:15-28.

   , ,

2. Dr ER, Dr DC, Dr SR. (2022) .Journal of Ophthalmic Research 25:112-125.

   , ,

3. Dr ML, Dr JW, Dr SK. (2024) .Clinical and Experimental Optometry 47:45-58.

   , ,

4. Dr EB, Dr TG, Dr OM. (2023) .Contact Lens and Anterior Eye 46:201-215.

   , ,

5. Dr JW, Dr IB, Dr LT. (2022) .Ophthalmology 129:87-99.

   , ,

6. Dr NM, Dr AH, Dr WJ. (2024) .Investigative Ophthalmology & Visual Science 65:305-318.

   , ,

7. Dr SA, Dr HW, Dr MY. (2023) .British Journal of Ophthalmology 107:1401-1410.

   , ,

8. Dr EG, Dr CT, Dr LH. (2022) .Nature Eye 4:567-578.

   , ,

9. Dr GL, Dr DK, Dr SS. (2024) .American Journal of Ophthalmology 258:95-108.

   , ,

10. Dr OW, Dr VA, Dr GM. (2023) .Optometry Times 18:30-38.

    , ,